Analysts Set Expectations for Mesoblast FY2025 Earnings

Mesoblast Limited (NASDAQ:MESO - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for Mesoblast in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings per share of ($0.70) for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Mesoblast's current full-year earnings is ($0.70) per share.

Several other research firms have also recently commented on MESO. Piper Sandler reiterated an "overweight" rating and issued a $24.00 price target (up previously from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Jefferies Financial Group downgraded shares of Mesoblast from a "buy" rating to a "hold" rating in a research report on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $18.00.

Mesoblast Stock Down 3.0 %

MESO stock traded down $0.40 during trading on Thursday, reaching $13.07. The stock had a trading volume of 432,858 shares, compared to its average volume of 796,175. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The firm has a fifty day moving average price of $17.77 and a 200 day moving average price of $12.47. Mesoblast has a 1-year low of $2.05 and a 1-year high of $22.00.

Remove Ads

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Bank of America Corp DE raised its position in shares of Mesoblast by 1,503.3% during the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock valued at $5,756,000 after acquiring an additional 272,595 shares in the last quarter. Oaktree Capital Management LP bought a new stake in Mesoblast during the fourth quarter valued at $3,556,000. Strategic Financial Concepts LLC acquired a new stake in shares of Mesoblast during the fourth quarter worth $2,744,000. Prosperity Wealth Management Inc. lifted its position in shares of Mesoblast by 2.0% in the 4th quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company's stock worth $1,846,000 after buying an additional 1,795 shares during the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company's stock valued at $695,000 after buying an additional 26,959 shares during the period. Institutional investors own 1.43% of the company's stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.